Curasight A/S announced that it has initiated pre-clinical studies of uPAR targeted radionuclide therapy in head and neck cancer and in neuroendocrine tumors. Results are expected to be available during first half of 2023. The study starts are in line with Curasight's expanded strategy to pursue therapy as well as diagnostics within head & neck cancer and neurodocrine tumors as announced in February this year.

The decision to expand into new therapeutic areas is based on the published positive results from investigator-initiated phase-II studies with diagnostic uTRACE in both indications.